CADTH Canadian Drug Expert Committee recommendation : indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a tumor necrosis factor-alpha inhibitor (TNFi). Tofacinitib (Xeljanz) / CADTH Canadian Drug Expert Committee.

Format:

Book

Author/Creator:

CADTH Canadian Drug Expert Committee, author, issuing body.

Language:

English

Subjects (All):

Ulcerative colitis.

Outcome assessment (Medical care).

Physical Description:

1 online resource (8 pages)

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2019.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be reimbursed for the treatment of adult patients with moderately to severely active UC with an inadequate response, loss of response, or intolerance to either conventional UCtherapy or a TNFi.

Notes:

Description based on publisher supplied metadata and other sources.